Skip to main content

Locally Advance Pancreatic Ductal Adenocarcinoma clinical trials at UCSF
1 in progress, 0 open to new patients

  • Phase II Trial of AZD6738 Alone and in Combination With Olaparib

    Sorry, not yet accepting patients

    This phase II trial studies how well ATR kinase inhibitor AZD6738 works alone or in combination with olaparib in treating participants with renal cell carcinoma, urothelial carcinoma, pancreatic ductal adenocarcinoma, or other solid tumors that have spread to nearby tissue or lymph nodes or other parts of the body. ATR kinase inhibitor AZD6738 and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not known if giving ATR kinase inhibitor AZD6738 with or without olaparib may work better in treating participants with solid tumors.

    San Francisco, California

Last updated: